Clinical Trials
22 trialsNCT01185158 2023-11-29
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
University of Chicago
Phase 2 Completed
NCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT00684385 2019-03-14
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
AstraZeneca
Approved for marketing
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT01405846 2016-08-19
TIDAL1
Papworth Hospital NHS Foundation Trust
Phase 2 Terminated
NCT00519077 2016-07-01
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00088907 2015-05-06
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00015964 2013-09-05
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00024089 2013-02-11
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00352105 2012-11-05
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00083057 2012-03-15
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00169221 2011-11-15
Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Terminated
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn
NCT00242762 2011-01-27
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
AstraZeneca
Phase 2 Completed
NCT00681967 2010-09-23
IRESSA&H&N
AstraZeneca
Phase 1 Completed
NCT00193284 2010-06-22
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00185835 2010-03-29
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Stanford University
Phase 1 Completed
NCT00242749 2009-04-23
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00255476 2009-04-23
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
AstraZeneca
Phase 2 Completed
NCT00228488 2007-12-19
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00239304 2007-12-18
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
AstraZeneca
Phase 1/2 Completed
NCT00195078 2007-07-20
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Weill Medical College of Cornell University
Phase 1/2 Terminated